TRT side effects are real but manageable — and the current evidence base is far more reassuring than it was a decade ago. TelosRX providers review testosterone optimization requests asynchronously, evaluating each case against current clinical research and provider-issued protocols.
The questions below come from the most common searches around testosterone replacement therapy. Answers are reviewed in the pharmacist and clinical tone used by the TelosRX team — no named individual is attributed, no outcomes are guaranteed, and every claim traces to published research.
Common TRT Side Effects: At a Glance
| Side Effect | Frequency | Management Approach |
|---|---|---|
| Erythrocytosis (elevated red blood cells) | Most common dose-related effect, especially injectable | Monitor hematocrit every 3–6 months; dose adjustment if >54% |
| Acne / oily skin | Common, particularly early in treatment | Skincare routine; topical treatments if persistent |
| Testicular atrophy / suppressed sperm production | Common with systemic TRT | hCG co-administration if fertility preservation is a goal |
| Fluid retention | Occurs in some patients | Monitor blood pressure; dose review if significant |
| PSA elevation (small, transient) | Documented in some studies | Baseline PSA before treatment; regular monitoring |
| Gynecomastia | Less common | Monitor estradiol levels; aromatase inhibitor if indicated |
| Sleep apnea worsening | Risk in predisposed individuals | Screen for OSA before and during treatment |
Q: What are the most common TRT side effects?
The most frequently reported side effects of testosterone replacement therapy include acne, oily skin, fluid retention, mood fluctuations, and changes in sexual function (often improved, sometimes variable). These tend to be most pronounced early in treatment and during dose adjustments.
The most clinically monitored side effect — particularly with injectable formulations — is erythrocytosis: an increase in red blood cell mass, reflected as elevated hemoglobin and hematocrit. A 2025 narrative review published in Cureus and indexed on PubMed Central identified erythrocytosis as "the most common dose-related adverse effect" of TRT, particularly with intramuscular injections.
Most side effects are manageable with appropriate monitoring and dose calibration. They are not reasons to categorically avoid TRT for eligible patients; they're reasons to evaluate carefully and monitor systematically.
Q: Does testosterone therapy affect cardiovascular health?
This was the most debated question in TRT research for over a decade. The picture has clarified considerably in recent years.
The TRAVERSE trial — a large, prospective, randomized, placebo-controlled study of over 5,200 men aged 45 to 80 — found that TRT did not increase the rate of major adverse cardiovascular events (MACE), including heart attack and stroke. The FDA subsequently removed the long-standing cardiovascular black box warning from testosterone products in 2025, reflecting this updated evidence base.
Earlier observational studies, including some VA database analyses, showed conflicting results. A thorough 2014 review indexed on PubMed Central noted that industry-funded and non-industry-funded trials reached opposite conclusions about cardiovascular risk — a pattern that underscores the importance of interpreting individual studies carefully rather than relying on any single data point.
Current clinical consensus: TRT prescribed appropriately to restore physiologic levels — not supraphysiologic levels — does not appear to increase cardiovascular risk in most men. The key phrase is physiologic levels. Supraphysiologic dosing carries a different risk profile.
Q: Can TRT cause prostate cancer?
This concern has its roots in older research and has been largely revised by more recent, larger-scale data.
The 2025 Cureus narrative review states directly: "TRT in men without active prostate cancer does not increase the incidence of prostate cancer or accelerate its progression." Small, transient increases in PSA (prostate-specific antigen) — typically 0.3 to 0.44 ng/mL based on reviewed data — have been documented, but these remained within clinically acceptable ranges and were not associated with cancer progression in large cohorts.
Standard clinical practice includes a baseline PSA measurement before starting TRT and periodic monitoring thereafter. TRT is generally contraindicated in men with active or suspected prostate cancer. Men with a history of prostate cancer who are considering TRT require individualized evaluation with a specialist — this is not a population for asynchronous initiation.
Q: Does TRT affect fertility?
Yes, and this is one of the most practically significant side effects for men of reproductive age. Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal (HPG) axis. When the brain detects adequate testosterone in circulation, it reduces luteinizing hormone (LH) and follicle-stimulating hormone (FSH) signaling — which means the testes reduce natural testosterone production and sperm production (spermatogenesis).
For many men, this suppression is reversible upon stopping TRT, particularly if duration of use has been limited. For men who want to preserve fertility while on TRT, human chorionic gonadotropin (hCG) — which mimics LH — is typically co-administered to maintain testicular stimulation. Our gonadorelin for TRT guide covers how GnRH analogs are used alongside testosterone therapy to maintain HPG axis function.
Men who want to start a family in the near term should discuss this explicitly with their provider before initiating TRT. Any testosterone protocol is subject to medical approval by a licensed provider.
Q: What is erythrocytosis and how is it managed on TRT?
Erythrocytosis means an elevated concentration of red blood cells — measured as hematocrit (the proportion of blood volume made up by red cells) or hemoglobin. Testosterone stimulates erythropoiesis (red blood cell production) in bone marrow. This effect is dose-dependent and more pronounced with injectable formulations than topical gels.
Published data shows statistically significant hemoglobin increases of approximately 0.86 g/dL on average, though individual variation is substantial. Elevated hematocrit can increase blood viscosity, which raises theoretical concerns about clotting risk — though the TRAVERSE trial and other large studies did not find increased stroke or thromboembolism in treated men at physiologic doses.
Management: hematocrit is monitored every 3 to 6 months. If it exceeds 54%, dose reduction, switching delivery method, or therapeutic phlebotomy are the standard interventions. This is not a reason to avoid TRT — it's a reason to monitor it. Learn more about what comprehensive hormone optimization protocols typically involve.
Q: Does TRT cause acne or skin changes?
Yes, acne and oilier skin are among the more common early side effects of TRT. Testosterone stimulates sebaceous gland activity — the same mechanism behind puberty-related acne. This is more pronounced in men with a pre-existing tendency toward acne.
For most men, skin side effects are mild and peak in the first few months of treatment. A consistent skincare routine — gentle cleansing, non-comedogenic moisturizer — manages it adequately in most cases. If acne is persistent or severe, topical retinoids or a dose review may be warranted.
Q: Is TRT safe for long-term use?
The evidence base for long-term TRT safety has grown substantially. The 2025 Cureus review covering men 50 and above documented improvements in lean body mass (+1.62 kg), fat mass reduction (-1.45 kg), lumbar spine bone mineral density (+7.5%), hip BMD (+3.3%), and metabolic markers over one year of treatment. These are therapeutic benefits, not just maintenance — and they compound over time when monitored and managed properly.
The primary safety requirement for long-term use is monitoring: hematocrit, PSA, lipid panel, blood pressure, and symptom assessment at regular intervals. Long-term safety is not guaranteed by the drug itself — it's maintained by consistent clinical oversight.
TelosRX's asynchronous model is built for ongoing evaluation, not just initiation. Providers review labs and health updates on their schedule. If you're evaluating whether TRT might be appropriate for your situation, our TRT telehealth guide covers the evaluation process in detail. All testosterone protocols are subject to medical approval by a licensed provider.
Frequently Asked Questions
How long until TRT side effects appear?
Some side effects — like acne, oily skin, and fluid retention — can appear within the first 2 to 4 weeks. Erythrocytosis develops more gradually, typically tracked at the 3-month mark. Positive effects on mood and libido often emerge in 2 to 4 weeks; body composition changes require 3 to 6 months. Individual response timelines vary significantly based on formulation, dose, and baseline health.
Can TRT cause hair loss?
Testosterone converts to dihydrotestosterone (DHT) via the enzyme 5-alpha reductase. DHT accelerates hair loss in men genetically predisposed to male-pattern baldness. TRT can accelerate this process if you carry the genetic susceptibility. It doesn't cause hair loss in men without the predisposition. If hair preservation is a concern, discuss this explicitly with your provider before starting — DHT blockers can sometimes be co-administered, though they carry their own considerations.
Does TRT cause mood swings?
Studies report improvements in mood, energy, and cognitive function in men with documented hypogonadism. However, dose instability — particularly with less frequent injections — can create peaks and troughs in testosterone levels that some men experience as mood variability. Switching to more frequent dosing or a different delivery method (such as daily subcutaneous injections or topical gels) often smooths this out. Mood effects are manageable with proper dose titration.
What happens if you stop TRT suddenly?
Stopping exogenous testosterone abruptly means the HPG axis must restart endogenous production — a process that takes weeks to months and isn't guaranteed to return to pre-TRT baseline. During this period, testosterone levels may be very low, leading to fatigue, low libido, and mood depression. A structured taper or post-cycle protocol (sometimes including hCG or clomiphene) managed by a licensed provider helps the axis recover more reliably. Do not stop TRT without a plan reviewed by your provider.
How do I know if TRT is right for me?
TRT is indicated for men with documented hypogonadism — low testosterone confirmed by morning serum blood testing combined with relevant symptoms such as fatigue, low libido, mood changes, or reduced physical performance. Testosterone levels alone are not sufficient; symptoms matter. The evaluation process at TelosRX involves reviewing your health history, symptoms, and lab results asynchronously — a licensed provider then issues a protocol recommendation. See our guide on low testosterone symptoms for context. Access is subject to provider evaluation and approval; it is not guaranteed.
TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service.
Start your private evaluation at TelosRX.